

Press release

23 April 2025

Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025

Copenhagen, Denmark, 23 April 2025 – today Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) held an Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

Today, the shareholders in Curasight passed the following resolutions at an Extraordinary General Meeting in accordance with the agenda:

1. Proposals from the Board of Directors

1.1 Extension and increasement of authorisations for the Board of Directors to increase the share capital

a. Extension and increasement of authorisations for the Board of Director to increase the share capital with pre-emption rights

A proposal from the Board of Directors to extend and increase the authorisation for the Board of Directors to increase the share capital with pre-emption rights in Article 5.1.1 of the Articles of Association was unanimously adopted with all votes represented at the general meeting. Consequently, the Company's Articles of Association will be updated to incorporate the following amendments:

<i>5</i>	<i>Bemyndigelser</i>	<i>Authorisations</i>
<i>5.1</i>	<i>Bemyndigelser til forhøjelse af aktiekapitalen</i>	<i>Authorisations to increase of the share capital</i>
<i>5.1.1</i>	<i>Selskabets bestyrelse er bemyndiget til i perioden til og med 21. marts 2029 ad en eller flere gange at forhøje selskabets aktiekapital med op til i alt nominelt kr. 100.000.000 aktier. Kapitalforhøjelser skal ske ved fuld kontant betaling og med fortegningsret for selskabets eksisterende aktionærer til en kurs fastsat af bestyrelsen, der kan være under markedskursen på tidspunktet for bestyrelsens beslutning.</i>	<i>Until and including 21 March 2029, the board of directors shall be authorised to increase the Company's share capital in one or more issues by up to a total nominal amount of DKK 100,000,000 shares. Capital increases must be paid up in full in cash with pre-emption right for the company's existing shareholders at a price determined by the board of directors, which may be below market price at the time of the decision of the board of directors.</i>

b. Extension and increasement of authorisation for the Board of Directors to increase the share capital without pre-emption rights

A proposal from the Board of Directors to extend and increase the authorisation for the Board of Directors to increase the share capital without pre-emption rights in Article 5.1.2 of the Articles of Association was unanimously adopted with all votes represented at the general meeting. Consequently, the Company's Articles of Association will be updated to incorporate the following amendments:

- | | |
|---|--|
| <p>5.1.2 <i>Selskabets bestyrelse er bemyndiget til i perioden til og med 21. marts 2029 ad en eller flere gange at forhøje selskabets aktiekapital med op til i alt nominelt kr. 100.000.000 aktier. Kapitalforhøjelser kan ske ved fuld kontant betaling, ved indbetaling af andre værdier end kontanter (apportindskud) eller ved konvertering af gæld eller som en kombination heraf. Kapitalforhøjelser skal ske til en kurs, der fastsættes af bestyrelsen, der kan være under markedskursen på tidspunktet for bestyrelsens beslutning, og skal ske uden fortegningsret for selskabets eksisterende aktionærer</i></p> | <p><i>Until and including 21 March 2029, the board of directors shall be authorised to increase the Company's share capital in one or more issues by up to a total nominal amount of DKK 100,000,000 shares. Capital increases may be carried out by payment in full of cash contribution, in-kind contribution of assets other than cash (contribution in kind) or through conversion of debt or a combination thereof. Capital increases shall be effected at a price to be determined by the board of directors, which may be below market price at the time of the decision of the board of directors, and without pre-emption right for the existing shareholders</i></p> |
|---|--|

c. Amendment of the total amount with which the share capital may be increased by utilization of the authorisation in items 1.1a and 1.1.b

Due to the adoption of items 1.1a and 1.1b a proposal from the Board of Directors, to amend article 5.1.3 of the Company's Articles of Association, which states how much the total share capital can be increased under the authorisations in article 5.1.1 and 5.1.2, was unanimously adopted with all votes represented at the general meeting. Consequently, the Company's Articles of Association will be updated to incorporate the following amendments:

- | | |
|--|---|
| <p>5.1.3 <i>Bemyndigelserne i pkt. 5.1.1 og 5.1.2 kan tilsammen ikke overstige nominelt kr.100.000.000 aktier.</i></p> | <p><i>The authorisations set out in articles 5.1.1 and 5.1.2 cannot, in the aggregate, exceed a nominal amount of DKK 100,000,000 shares.</i></p> |
|--|---|

1.2 Authorisation for the Board of Directors to issue warrants

A proposal from the Board of Directors, to introduce a warrant authorization to the Board of Directors in the Company's Articles of Association, was unanimously adopted with all votes represented at the general meeting. Consequently, the Company's Articles of Association will be updated to incorporate the following new article:

5.2.6 *Selskabets bestyrelse er bemyndiget til af én eller flere gange i henhold til selskabslovens §155, jf. §169, at udstede op til 106.375.256 warrants i Selskabet med ret til tegning af op til i alt nominelt 5.318.812 kr. kapitalandele i Selskabet uden fortegningsret for de eksisterende kapitalejere i Selskabet til en kurs og fordeling, som fastlægges af bestyrelsen. Kursen kan være under markedskursen på tidspunktet for bestyrelsens beslutning.*

Samtidig er bestyrelsen bemyndiget til at foretage den dertil hørende forhøjelse af Selskabets aktiekapital ad en eller flere omgange med nominelt 5.318.812 kr., eller et andet beløb som følge af eventuel regulering af antallet af udstedte warrants, antallet af kapitalandele, som de udstedte warrants giver ret til at tegne, og/eller tegningskursen i henhold til de til enhver tid gældende vilkår for de udstedte warrants.

Bemyndigelsen løber frem til 16. april 2030. Aktier udstedt i henhold til bemyndigelsen i dette pkt. 5.2.6 skal indbetales fuldt ud ved gældskonvertering eller kontant indskud, være omsætningspapirer, skal lyde på navn og noteres på navn i Selskabets ejerbog. Der gælder samme indskrænkninger i aktiernes omsættelighed, som gælder for de eksisterende aktier og ingen aktionær er forpligtet til at lade aktier indløse helt eller delvist.

Bestyrelsen er bemyndiget til at genanvende eller genudstede eventuelle bortfaldne ikke-udnyttede warrants, forudsat at genanvendelsen eller genudstedelsen finder sted inden for de vilkår og tidsmæssige begrænsninger, der fremgår af bemyndigelsen.

The Company's board of directors is authorised, pursuant to s. 155 of the Danish Companies Act, cf., s. 169 thereof, in one or several instances, to issue up to a total of 106,376,256 warrants, which will entitle their holder(s) to subscribe for up to a total of nominally DKK 5,318,812 shares in the Company without pre-emption rights for the existing shareholders at a subscription price and allocation determined by the board of directors. The subscription price may be below the market price at the time of the decision of the board of directors.

The Company's board of directors is also authorised to carry out any related share capital increases, in one or several instances, up to a total of nominally DKK 5,318,812 or such other amount as required following an adjustment of the number of warrants, the numbers of shares that issued warrants entitle the holder(s) to subscribe and/or the exercise price in accordance with the terms governing the issued warrants.

The authorization is valid until 16 April 2030. Shares issued pursuant to the authorization in this clause 5.2.6 must be paid up in full by conversion of debt or by cash payment, be negotiable instruments, be registered by name and be registered by the name of shareholders in the Company's shareholders' register. The same restrictions on transferability as those applying to the existing shares apply and no shareholder shall be obligated to have the shares redeemed partly or in full.

The board of directors is authorized to reuse or reissue any lapsed, non-exercised warrants, provided that such reuse or reissuance observes the terms, and the expiration date set out in this authorization.

1.3 Authorisation to the chairman of the meeting

The general meeting adopted a resolution to authorise the chairman of the meeting Ulrik Bangsbo Hansen, with full right of substitution, to apply for registration of the resolutions passed and to make certain amendments, if necessary.



PROVIDING ANSWERS FOR CANCER PATIENTS

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.